Filing Flows › Amphastar Pharmaceuticals (AMPH) › Q2 2026 › vs Q1 2026
Amphastar Pharmaceuticals (AMPH) Q2 2026 vs Q1 2026 (quarter over quarter)
Amphastar Pharmaceuticals's revenue rose $12.7M (+7%) from $171M in Q1 2026 to $184M in Q2 2026. Gross margin 50.8% against 41.1% (+9.7 pts).
Amphastar Pharmaceuticals, Q2 2026: revenue $184M (+5% year over year), operating margin 21.6%, net earnings $30.3M, operating cash flow $51.3M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 50.8% | 41.1% | +9.7 pts |
| Operating margin | 21.6% | 8.0% | +13.6 pts |
| Net margin | 16.5% | 3.8% | +12.8 pts |
| Free cash flow margin | 23.2% | 22.4% | +0.8 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $184M | $171M | $12.7M | +7% |
| Gross profit | $93.5M | $70.3M | $23.1M | +33% |
| Cost of revenue | $90.4M | $101M | −$10.4M | -10% |
| Operating profit | $39.7M | $13.6M | $26.1M | +191% |
| Operating expenses | $53.7M | $56.7M | −$3.0M | -5% |
| Pre-tax earnings | $38.5M | $10.1M | $28.5M | +283% |
| Other expense, net | $1.2M | $3.6M | −$2.4M | -67% |
| Research & development | $22.2M | $26.7M | −$4.6M | -17% |
| Sales & marketing | $13.3M | $11.9M | $1.4M | +12% |
| General & admin | $18.2M | $18.0M | $214K | +1% |
| Net earnings | $30.3M | $6.4M | $23.9M | +373% |
| Income tax | $8.2M | $3.6M | $4.6M | +126% |
| Depreciation & amortization | $14.3M | $14.3M | −$37K | -0.3% |
| Share-based compensation | $7.1M | $9.3M | −$2.2M | -24% |
| Working capital & other | $425K | −$17.8M | $18.2M | — |
| Operating cash flow | $51.3M | $47.8M | $3.5M | +7% |
| Free cash flow (OCF − capex) | $42.7M | $38.3M | $4.4M | +11% |
| Capital expenditures | $8.6M | $9.5M | −$916K | -10% |
Questions
How much did Amphastar Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Amphastar Pharmaceuticals's revenue rose $12.7M (+7%) from $171M in Q1 2026 to $184M in Q2 2026. Gross margin 50.8% against 41.1% (+9.7 pts).